Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aref Al-Kali

Showing results (71-80 of 148) with videos related to

Pageof 15
Sort By:
Leukemia & Lymphoma|May 10, 2017
Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy<sup/>Jason N Barreto, Kristen B McCullough, Candy S Peskey, et al.
American Journal of Hematology|April 10, 2019
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patientsTucker Coston, Prateek Pophali, Rangit Vallapureddy, et al.
American Journal of Hematology|May 13, 2022
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasmsMithun Vinod Shah, Rakchha Chhetri, Ruchita Dholakia, et al.
Blood Cancer Journal|February 2, 2022
Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patientsAbhishek A Mangaonkar, Terra L Lasho, Rhett P Ketterling, et al.
Haematologica|May 14, 2026
<i>CSF3R</i>-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patientsAbiola B Bolarinwa, Natasha Szuber, Janick Caron-Lecuyer, et al.
Blood Advances|April 2, 2024
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significanceMarissa Li, Anmol Baranwal, Mark Gurney, et al.
Mayo Clinic Proceedings|November 8, 2015
Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 PatientsNaseema Gangat, Mrinal M Patnaik, Kebede Begna, et al.
Blood Cancer Journal|July 8, 2022
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasmsMithun Vinod Shah, Abhishek A Mangaonkar, Kebede H Begna, et al.
British Journal of Haematology|February 4, 2024
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agentsIsla M Johnson, Omer Karrar, Masooma Rana, et al.
American Journal of Hematology|April 12, 2021
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive casesNaseema Gangat, Paola Guglielmelli, Natasha Szuber, et al.
Pageof 15

Showing results (71-80 of 148) with videos related to

Sort By:
Pageof 15
Leukemia & Lymphoma|May 10, 2017
Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy<sup/>Jason N Barreto, Kristen B McCullough, Candy S Peskey, et al.
American Journal of Hematology|April 10, 2019
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patientsTucker Coston, Prateek Pophali, Rangit Vallapureddy, et al.
American Journal of Hematology|May 13, 2022
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasmsMithun Vinod Shah, Rakchha Chhetri, Ruchita Dholakia, et al.
Blood Cancer Journal|February 2, 2022
Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patientsAbhishek A Mangaonkar, Terra L Lasho, Rhett P Ketterling, et al.
Haematologica|May 14, 2026
<i>CSF3R</i>-mutated chronic neutrophilic leukemia: a two-center study of 44 consecutive patientsAbiola B Bolarinwa, Natasha Szuber, Janick Caron-Lecuyer, et al.
Blood Advances|April 2, 2024
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significanceMarissa Li, Anmol Baranwal, Mark Gurney, et al.
Mayo Clinic Proceedings|November 8, 2015
Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 PatientsNaseema Gangat, Mrinal M Patnaik, Kebede Begna, et al.
Blood Cancer Journal|July 8, 2022
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasmsMithun Vinod Shah, Abhishek A Mangaonkar, Kebede H Begna, et al.
British Journal of Haematology|February 4, 2024
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agentsIsla M Johnson, Omer Karrar, Masooma Rana, et al.
American Journal of Hematology|April 12, 2021
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive casesNaseema Gangat, Paola Guglielmelli, Natasha Szuber, et al.
Pageof 15